Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression

Journal of Thoracic Oncology

Volumn 8, Issue 12, 2013, Pages 1492-1501

  Guin, Sunny ^a,b   Ru, Yuanbin ^a,b   Wynes, Murry W ^b   Mishra, Rangnath ^c   Lu, Xian ^a   Owens, Charles ^a,b   Barón, Anna E ^b   Vasu, Vihas T ^c   Hirsch, Fred R ^a,b   Kern, Jeffrey A ^a,b   Theodorescu, Dan ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

Author keywords

GTPase; Non small cell lung cancer; Prognosis; RAL; RAS

Indexed keywords

GLYCINE; K RAS PROTEIN; RAL PROTEIN; KRAS PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; RALA PROTEIN, HUMAN; RALB PROTEIN, HUMAN; RAS PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MUTANT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TRANSCRIPTOMICS; WILD TYPE; ANIMAL; APOPTOSIS; CANCER STAGING; CELL PROLIFERATION; ENZYME IMMUNOASSAY; GENETICS; LUNG TUMOR; METABOLISM; MORTALITY; MOUSE; NON SMALL CELL LUNG CANCER; NUDE MOUSE; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAL GTP-BINDING PROTEINS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84892146436     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000007     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-465.
3. Okudela K, Woo T, Kitamura H. KRAS gene mutations in lung cancer: particulars established and issues unresolved. Pathol Int 2010;60:651-660.
4. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-205.
5. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010;29:49-60.
6. Santos E, Martin-Zanca D, Reddy E P, Pierotti MA, Della Porta G, Barbacid M. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 1984;223:661-664.
7. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317:929-935.
8. Forbes S, Clements J, Dawson E, et al. COSMIC 2005. Br J Cancer 2006;94:318-322.
9. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131-139.
10. Lim KH, O'Hayer K, Adam SJ, et al. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 2006;16:2385-2394.
11. Yin J, Pollock C, Tracy K, et al. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol 2007;27:7538-7550.
12. Martin TD, Samuel JC, Routh ED, Der CJ, Yeh JJ. Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res 2011;71:206-215.
13. Gildea JJ, Harding MA, Seraj MJ, Gulding KM, Theodorescu D. The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res 2002;62:982-985.
14. Bodemann BO, White MA. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer 2008;8:133-140.
15. Peschard P, McCarthy A, Leblanc-Dominguez V, et al. Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis. Curr Biol 2012;22:2063-2068.
16. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104:228-239.
17. Oxford G, Owens CR, Titus BJ, et al. RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res 2005;65:7111-7120.
18. Gagliardi PA, di Blasio L, Orso F, et al. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner. Neoplasia 2012;14:719-731.
19. Wang H, Owens C, Chandra N, Conaway MR, Brautigan DL, Theodorescu D. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis. Cancer Res 2010;70:8760-8769.
20. Feig LA. Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol 2003;13:419-425.
21. Smith SC, Baras AS, Owens CR, Dancik G, Theodorescu D. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res 2012;72:3480-3491.
22. Kishida S, Koyama S, Matsubara K, Kishida M, Matsuura Y, Kikuchi A. Colocalization of Ras and Ral on the membrane is required for Rasdependent Ral activation through Ral GDP dissociation stimulator. Oncogene 1997;15:2899-2907.
23. Matsubara K, Kishida S, Matsuura Y, Kitayama H, Noda M, Kikuchi A. Plasma membrane recruitment of RalGDS is critical for Ras-dependent Ral activation. Oncogene 1999;18:1303-1312.
24. Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009;15:489-500.